Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 301–400 of 1,003
Minimizing the Risk of Bleeding with NOACs in the Elderly
Kundu, A., Sardar, P., Chatterjee, S., Aronow, W. S., Owan, T., & Ryan, J. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0376-z · Cited by 58
“55) [27].”
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Stefano, V. D., Finazzi, G., & Barbui, T. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0101-8 · Cited by 58
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction
Hanni, C. M., Petrovitch, E. A., Ali, M. A., Gibson, W., Giuliano, C. A., Holzhausen, J. M., Makowski, C. T., Pallisco, A., Patel, N., Sutter, D. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000972 · Cited by 54
“Landmark studies comparing apixaban with warfarin in atrial fibrillation and acute venous thromboembolism (VTE) excluded individuals with creatinine clearance (CrCl) ,25 mL/min.(6-8) However, in 2014 the US Food and Drug Administration (FDA) approved apixaban for ESRD patients with atrial fibrillation based on limited…”
BackgroundAnticoagulation in chronic kidney disease: current status and future perspectives
Jones, A. P., Swan, D., Lisman, T., Barnes, G. D., & Thachil, J. V. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.09.020 · Cited by 62
New Approaches to Inhibiting Platelets and Coagulation
Depta, J. P., & Bhatt, D. L. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124438 · Cited by 55
Recent advances in the management of pulmonary embolism: focus on the critically ill patients
Meyer, G., Vieillard‐Baron, A., & Planquette, B. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0122-z · Cited by 63
“Among these drugs, rivaroxaban, dabigatran, apixaban and edoxaban have been compared with the standard treatment of low molecular weight heparin (LMWH) and warfarin in patients with VTE including low-risk or intermediate-risk PE patients in large phase III trials [35–40].”
BackgroundThe use of direct oral anticoagulants in chronic kidney disease
Parker, K., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15564 · Cited by 54
“Patients with chronic kidney disease (CKD) are at an increased of developing AF and VTE (Wattanakit et al, 2008; Albertsen et al, 2013).”
Cochran, J. M., Jia, X., Kaczmarek, J. V., Staggers, K. A., Rifai, M. A., Hamzeh, I., & Birnbaum, Y. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420967644 · Cited by 51
“DOACs are an attractive option with fewer drug interactions, no dietary restrictions, reduced need for monitoring, similar efficacy, and lower risk of intracranial bleeding in the treatment of other thromboembolic conditions as compared to VKA.(10-15) To date, no randomized trials exist to compare the treatment of LVT…”
BackgroundWu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Brunetti, N. D., Gesuete, E., Gennaro, L. D., Correale, M., Caldarola, P., Gaglione, A., & Biase, M. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.12.168 · Cited by 54
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art
Thaler, J., Pabinger, I., & Ay, C. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00030 · Cited by 58
“In the Amplify study investigating Apixaban for the treatment of acute VTE patients with a transient risk factor and “less than 6months of anticoagulant treatment planned” were excluded (13).”
BackgroundAssociation rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban
Jourdi, G., Siguret, V., Martin, A., Golmard, J., Godiér, A., Samama, C. M., Gaussem, P., Gouin‐Thibault, I., & Bonniec, B. L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0877 · Cited by 54
Harder, S. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-22 · Cited by 54
Drouet, L. O., Sollier, C. B. D., Steiner, T., & Purrucker, J. C. (2016) · International Journal of Stroke · doi:10.1177/1747493016659671 · Cited by 57
Howard, M. E., Lipshutz, A. M., Roess, B., Hawes, E. M., Deyo, Z. M., Burkhart, J. I., Moll, S., & Shilliday, B. B. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1435-3 · Cited by 52
Godin, R., Marcoux, V., & Tagalakis, V. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.001 · Cited by 53
Direct acting oral anticoagulants for the treatment of suspected heparin‐induced thrombocytopenia
Davis, K., & Davis, D. O. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12921 · Cited by 50
Kajy, M., Shokr, M., & Ramappa, P. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000937 · Cited by 52
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
Benamouzig, R., Guenoun, M., Deutsch, D., & Fauchier, L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07211-0 · Cited by 58
The role of factor Xa inhibitors in venous thromboembolism treatment
Cabral, K. P., & Ansell, J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s39726 · Cited by 50
“Apixaban has been studied for the treatment of acute VTE in the AMPLIFY study: a randomized, double-blinded, noninferiority trial.(19) A total of 5,395 patients with an acute DVT,”
Management of venous thromboembolism: an update
Piran, S., & Schulman, S. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0107-z · Cited by 53
“Major bleeding: 7 vs 16; Fatal bleeding: 0 vs 8a Major bleeding: 6 vs 4; Any bleeding 14 vs 19 Major bleeding: 7 vs 7; Any bleeding: 27 vs 24 Major bleeding: enoxaparin 1 mg vs. 1.5 mg vs VKA : 6.5 vs 11.1 vs 2.9 Major bleeding: 2.7 vs 2.4 CRNM bleeding: 10.9a vs 15.3 CRNM clinically relevant non-major, DOAC direct or…”
InfluentialEdoxaban: A direct oral anticoagulant
Poulakos, M. N., Walker, J. N., Baig, U., & David, T. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150821 · Cited by 57
Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
Montiel, F. S., Ghazvinian, R., Gottsäter, A., & Elf, J. L. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0149-x · Cited by 52
Huang, H., Liu, P. P., Hsu, J., Lin, S., Peng, C. C., Wang, J., & Loh, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz952 · Cited by 52
Wetmore, J. B., Herzog, C. A., Yan, H., Reyes, J. L., Weinhandl, E. D., & Roetker, N. S. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14021021 · Cited by 51
2020 Clinical practice guidelines for Myocarditis in adults
Arutyunov, G. P., Палеев, Ф. Н., Моисеева, О. М., Драгунов, Д. О., Sokolova, A. V., Arutyunov, A. G., Жиров, И. В., Blagova, O. V., Privalova, E. V., Габрусенко, С. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4790 · Cited by 56
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 56
Multimodal assessment of non‐specific hemostatic agents for apixaban reversal
Martin, A., Gouin‐Thibault, I., Siguret, V., Mordohay, A., Samama, C. M., Gaussem, P., Bonniec, B. L., & Godiér, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12830 · Cited by 51
Milling, T. J., & Frontera, J. A. (2017) · PubMed · Cited by 63
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome
Utne, K. K., Dahm, A. E. A., Wik, H. S., Jelsness‐Jørgensen, L., Sandset, P. M., & Ghanima, W. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.01.013 · Cited by 50
Wolfe, Z., Khan, S. U., Nasir, F., Subramanian, C. R., & Lash, B. W. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14131 · Cited by 51
Weycker, D. A., Li, X., Wygant, G. D., Lee, T. T. H., Hamilton, M., Luo, X., Vo, L., Mardekian, J., Pan, X., Burns, L. C., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1673689 · Cited by 52
Self-citationRadadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters
Tripodi, A., Padovan, L., Chantarangkul, V., Scalambrino, E., Testa, S., & Peyvandi, F. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.032 · Cited by 48
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
“To achieve equivalence to warfarin (Einstein Investigators, 2010, Agnelli et al, 2013) the peak anticoagulant effect of rivaroxaban could be higher than apixaban to accommodate the once daily dosing (Salem et al, 2015).”
BackgroundInfluentialKang, N., & Sobieraj, D. M. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.03.035 · Cited by 52
“2) [6–11].”
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 54
Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure
Raccah, B. H., Perlman, A., Danenberg, H. D., Pollak, A., Muszkat, M., & Matok, I. (2016) · CHEST Journal · doi:10.1016/j.chest.2015.12.029 · Cited by 51
“Patients with estimated creatinine clearance (eCrCL) < 30 mL/min for rivaroxaban, edoxaban, and dabigatran, and eCrCL < 25 mL/min for apixaban, were excluded from the Phase III trials.(15-23) Consequently, clinical practice guidelines call for careful use of DOACs in patients with RF and include recommendations for re…”
BackgroundSert, S. M., Mutlu, B., Kocakaya, D., Deniz, K., Halil, A., Erdoğan, O., & Yıldızeli, B. (2020) · Pulmonary Circulation · doi:10.1177/2045894019873545 · Cited by 49
Jakowenko, N. D., Nguyen, S. N., Ruegger, M. C., Dinh, A., Salazar, E., & Donahue, K. R. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.09.002 · Cited by 48
Peri-procedural management of patients taking oral anticoagulants
Daniels, P. R. (2015) · BMJ · doi:10.1136/bmj.h2391 · Cited by 47
Ko, D., Cove, C. L., & Hylek, E. M. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-12-1032 · Cited by 47
Basics of diagnosis and treatment of venous thromboembolism
Cox, C., & Roberts, L. N. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.01.009 · Cited by 50
Pharmacological reversal of the direct oral anticoagulants—A comprehensive review of the literature
Shaw, J. R., & Siegal, D. M. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12089 · Cited by 47
Sebastian, T., Hakki, L. O., Spirk, D., Baumann, F. A., Périard, D., Banyai, M., Spescha, R. S., Kucher, N., & Engelberger, R. P. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.10.027 · Cited by 46
Goggs, R. A. N., Bacek, L. M., Bianco, D., Koenigshof, A. M., & Li, R. H. L. (2019) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12791 · Cited by 50
Temporal Trends in the Practice Pattern for Venous Thromboembolism in Japan: Insight From JROAD‐DPC
Yamashita, Y., Morimoto, T., Yoshikawa, Y., Yaku, H., Sumita, Y., Nakai, M., Ono, K., & Kimura, T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014582 · Cited by 51
“Length of hospital stay in DVT patients, d 13 (8-21)”
BackgroundHoughton, D. E., Vlazny, D. T., Casanegra, A. I., Brunton, N. E., Froehling, D. A., Meverden, R. A., Hodge, D. O., Peterson, L. G., McBane, R. D., & Wysokiński, W. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.026 · Cited by 46
Cohen, A. T., Sah, J., Dhamane, A. D., Lee, T. T. H., Rosenblatt, L. C., Hlavacek, P., Emir, B., Delinger, R. L., Yüce, H., & Luo, X. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740254 · Cited by 50
Self-citationBurness, C. B., & Perry, C. M. (2014) · Drugs · doi:10.1007/s40265-013-0174-4 · Cited by 50
“Furthermore, apixaban demonstrated noninferior efficacy to conventional therapy (subcutaneous enoxaparin sodium, followed by warfarin) in 5,395 patients with acute VTE and was associated with significantly less bleeding in the AMPLIFY trial [88].”
BackgroundGaertner, S., Cordeanu, E., Nouri, S., Faller, A., Frantz, A., Mirea, C., Bilbault, P., Ohlmann, P., Ray, I. L., & Stéphan, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.045 · Cited by 50
Eerenberg, E. S., Cohen, A. T., Middeldorp, S., Raskob, G. E., Buller, H. R., Bleker, S. M., & Brekelmans, M. P. A. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0946 · Cited by 47
“35 (19) 18 (10) 13 (7) 2 (1) 2 (1) 59 (33) 10 (6) 5 (3) 10 (6) 17 (9) 8 (4) 14 (8) 5 (3) 17 (9)”
Self-citationEvidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 48
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties
Pinto, D. J. P., Smallheer, J. M., Corte, J. R., Austin, E. J. D., Wang, C., Fang, T., Smith, L. M., Rossi, K. A., Rendina, A. R., Bozarth, J. M., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.028 · Cited by 45
Song, Y., Chang, M., Suzuki, A., Frost, R. J. A., Kelly, A., LaCreta, F., & Frost, C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.004 · Cited by 43
Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes
Meyer, G. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2014.05.006 · Cited by 48
Antiphospholipid syndrome: an update
Merashli, M., Noureldine, M. H. A., Uthman, I. W., & Khamashta, M. A. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12449 · Cited by 47
Ageno, W., & Beyer‐Westendorf, J. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
Bertoletti, L., Ollier, É., Duvillard, C., Delavenne, X., Beyens, M., Magalhaes, É. D., Bellet, F., Basset, T., Mismetti, P., & Laporte, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.023 · Cited by 47
“Randomized studies in the acute treatment of VTE Pooled analysis of RE-COVER and RE-COVER2 [40] 5107 patients Pooled analysis of EINSTEIN-PE and EINSTEIN-DVT [59] 8281 patients AMPLIFY [42]”
InfluentialRusso, V., Rago, A., Proietti, R., Meo, F. D., Papa, A. A., Calabrò, P., D’Onofrio, A., Nigro, G., & AlTurki, A. (2016) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098616673990 · Cited by 44
Sindet-Pedersen, C., Pallisgaard, J. L., Staerk, L., Berger, J. S., Lamberts, M., Torp-Pedersen, C., Gislason, G. H., & Olesen, J. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-03596-x · Cited by 44
Sartori, M., & Cosmi, B. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1617-2 · Cited by 44
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
“In regard to treatment for VTE, apixaban was shown to be non-inferior to enoxaparin [106,107].”
BackgroundAn Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
Mujer, M. T. P., Rai, M. P., Atti, V., Dimaandal, I., Chan, A. S., Shrotriya, S., Gundabolu, K., & Dhakal, P. (2020) · Advances in Hematology · doi:10.1155/2020/7636104 · Cited by 50
“Twice-daily apixaban could be preferred for its safety profile, as shown by the 69% reduction in major bleeding [9], also since United States Food and Drug Administration (FDA) recently approved generics of apixaban making it more affordable.”
BackgroundDirect Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus
Willeford, A., Zhu, W., Stevens, C., & Thomas, I. C. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020975111 · Cited by 46
Apixaban and rivaroxaban in patients with acute venous thromboembolism
Bott-Kitslaar, D. M., McBane, R. D., Casanegra, A. I., Houghton, D. E., Froehling, D. A., Vlazny, D. T., Ashrani, A. A., Hodge, D. O., Vargas, E. R., Bartlett, M. A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.022 · Cited by 43
Fang, M. C., Reynolds, K., Fan, D., Prasad, P. A., Sung, S. H., Portugal, C., Garcia, E. A., & Go, A. S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.28033 · Cited by 49
Jannati, S., Patnaik, R., & Banerjee, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168727 · Cited by 47
Managing pulmonary embolism from presentation to extended treatment
Cohen, A. T., Dobromirski, M., & Gurwith, M. M. P. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.09.040 · Cited by 49
“This study included a higher number of patients with PE than the other mixed VTE studies (n = 3319) [78,79], and a high proportion of these (approximately 46%) had anatomically extensive disease.”
BackgroundResultSelf-citationDiagnosis and management of pulmonary embolism in the elderly
Robert‐Ebadi, H., & Righini, M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.009 · Cited by 43
“Current NOA can be divided in two classes: direct thrombin inhibitors (DTI) represented by dabigatran studied in VTE in the RECOVER trial [88] and direct factor Xa inhibitors represented by rivaroxaban (EINSTEIN studies) [89,90], apixaban (AMPLIFY study) [91] and edoxaban (HOKUSAI study) [92].”
BackgroundBarco, S., Lankeit, M., Binder, H., Schellong, S., Christ, M., Beyer‐Westendorf, J., Duerschmied, D., Bauersachs, R. M., Empen, K., Held, M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-01-0004 · Cited by 48
“In the meantime, four non-vitamin K–dependent oral anticoagulants (apixaban, dabigatran, edoxaban, and rivaroxaban) have been approved for the treatment and secondary prophylaxis of VTE, and two of them were successfully tested in a ‘single oral drug’ regimen which may facilitate the early transition from hospital to…”
BackgroundApixaban for the treatment of cerebral venous thrombosis: A case series
Rao, S. K., Ibrahim, M., Hanni, C. M., Suchdev, K., Parker, D. L., Rajamani, K., & Mohamed, W. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.09.007 · Cited by 43
Allison, T. A., Lin, P. J., Gass, J. A., Chong, K., Prater, S. J., Escobar, M. A., & Hartman, H. (2018) · Journal of Intensive Care Medicine · doi:10.1177/0885066618800657 · Cited by 44
“3) Admission scores, median (IQR) APACHE II score 20 (15-26) Glasgow coma score 15 (11-15) Required surgery, n (%) 6 (18.”
BackgroundAndexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
Carpenter, E. M. L., Singh, D., Dietrich, E. A., & Gums, J. G. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619888133 · Cited by 43
Platelets in Advanced Chronic Kidney Disease: Two Sides of the Coin
Lutz, P. D. M. J., & Jurk, P. D. R. N. K. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1708841 · Cited by 44
Percutaneous interventions for pulmonary embolism
Finocchiaro, S., Mauro, M. S., Rochira, C., Spagnolo, M., Laudani, C., Landolina, D., Mazzone, P. M., Agnello, F. G., Ammirabile, N., Faro, D. C., et al. (2024) · EuroIntervention · doi:10.4244/eij-d-23-00895 · Cited by 50
Wu, C. M., Alotaibi, G., AlSaleh, K. A., Linkins, L., & McMurtry, M. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.033 · Cited by 43
“Recently, four direct oral anticoagulant agents (DOACS; apixaban, dabigatran, rivaroxaban, and edoxaban), have been shown to be noninferior to VKAs for the initial treatment of VTE [10–14].”
BackgroundGerotziafas, G., Mahé, I., & Elalamy, I. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s49063 · Cited by 47
“0 (n=2,635).(32) The primary efficacy outcome was recurrent symptomatic VTE or death related to VTE.”
BackgroundNew anticoagulants for the treatment of venous thromboembolism
Fernandes, C. J. C. D. S., Alves, J. L., Gavilanes, F., Prada, L. F., Morinaga, L. T. K., & Souza, R. (2016) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562016042020068 · Cited by 70
“Apixaban Factor Xa inhibitor Agnelli et al.(23,24) Apixaban 10 mg every 12 h for 7 days; 5 mg every 12 h 6 Apixaban (2.3”
BackgroundInfluentialYamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.08.2206 · Cited by 43
Castillo, R., Chan, A., Atallah, S., Derry, K. L., Baje, M., Zimmermann, L. L., Martin, R., Groysman, L. I., Stern-Nezer, S. J., Minokadeh, A., et al. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02154-z · Cited by 42
Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review
Cai, Q., Zhang, X., & Chen, H. (2021) · Thrombosis Journal · doi:10.1186/s12959-021-00345-z · Cited by 44
“Agnelli [95] (2013) Randomized trial 5395 Apixaban Enoxaparin, followed by warfarin 2.”
BackgroundBleker, S. M., van Es, N., van Gils, L., Daams, J. G., Kleinjan, A., Buller, H. R., & Nisio, M. D. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30104-9 · Cited by 45
Self-citationMeta-analysis on risk of bleeding with apixaban in patients with renal impairment
Pathak, R., Pandit, A., Karmacharya, P., Aryal, M. R., Ghimire, S., Poudel, D. R., & Shamoun, F. E. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.042 · Cited by 41
Kumano, O., Akatsuchi, K., & Amiral, J. (2021) · Biomedicines · doi:10.3390/biomedicines9030264 · Cited by 45
Anticoagulant use in older persons at risk for falls: therapeutic dilemmas—a clinical review
Mitchell, A., Elmasry, Y. E. T., van Poelgeest, E. P., & Welsh, T. J. (2023) · European Geriatric Medicine · doi:10.1007/s41999-023-00811-z · Cited by 44
“The pivotal trials for the use of DOACs to prevent VTE recurrence showed them to be non-inferior to conventional therapy (subcutaneous enoxaparin followed by warfarin), with lower (apixaban and edoxaban) [47, 48] or similar (dabigatran and rivaroxaban) [49–52] rates of major bleeding.”
BackgroundMar, P. L., Familtsev, D., Ezekowitz, M. D., Lakkireddy, D., & Gopinathannair, R. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.035 · Cited by 43
Direct Oral Anticoagulants in Cirrhosis
Intagliata, N. M., Maitland, H. S., & Caldwell, S. H. (2016) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-016-0092-0 · Cited by 41
Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
Turpie, A. G. G., Purdham, D. M., & Ciaccia, A. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717714921 · Cited by 44
Arthrocentesis and Joint Injection in Patients Receiving Direct Oral Anticoagulants
Yui, J. C., Preskill, C., & Greenlund, L. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.007 · Cited by 41
Progress in the monitoring of direct oral anticoagulant therapy
Patel, J. P., Byrne, R., Patel, R., & Arya, R. (2019) · British Journal of Haematology · doi:10.1111/bjh.15756 · Cited by 44
Herndon, K., Guidry, T. J., Wassell, K., & Elliott, W. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019897053 · Cited by 41
“The Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY) study exhibited similar results regarding bleeding.(2) The results of these studies have made apixaban a popular drug of choice for these conditions.”
BackgroundResultRivaroxaban for the treatment of venous thromboembolism
Aujesky, D., Beer, J. H., Mazzolai, L., Baldi, T., Banyai, M., Hayoz, D., Kaeslin, T., Korte, W. C., Escher, R., Husmann, M. J. W., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0209 · Cited by 42
Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures
Deutsch, D., Boustière, C., Ferrari, É., Albaladejo, P., Morange, P., & Benamouzig, R. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17702092 · Cited by 41
Myeloid-related protein-14 regulates deep vein thrombosis
Wang, Y., Gao, H., Kessinger, C. W., Schmaier, A. H., Jaffer, F. A., & Simon, D. I. (2017) · JCI Insight · doi:10.1172/jci.insight.91356 · Cited by 41
Drug interactions with new oral anticoagulants in elderly patients
Stöllberger, C. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1370369 · Cited by 47
“[1] Dabi RE-LY Man AF 18,113 40% 71 24 [2] Dabi RE-COVER I Man VTE 2,564 NR 54 6 [3] Dabi RE-COVER II Man VTE 2,589 NR 55 6 [4] Dabi RE-MEDY Man VTE 4,219 NR 55 16 [5] Apix ARISTOTLE Man AF 18,201 31% 70 22 [6] Apix AMPLIFY Man VTE 5,395 NR 57 6 [7] Riva ROCKET AF Man AF 14,264 38% 73 20 [8] Riva EINSTEIN DVT Man VTE…”
Wang, C., Wu, V. C., Lee, C., Kuo, C., Chen, Y., Chu, P., Chen, S., Wen, M., See, L., & Chang, S. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1792-1 · Cited by 42
Haas, S. K., Ageno, W., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., Zaghdoun, A., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14548 · Cited by 41
Self-citationGuo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
“On the contrary, there is also evidence that the risk of GI bleeding in patients taking oral apixaban is lower than that in the warfarin group.(5) However, no randomized-controlled trial (RCT) has directly compared the risk of GI bleeding following different NOAC regimens.”
ResultUse of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.